Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Background: The ECOG-ACRIN randomized phase 3 clinical trial E1912 established ibrutinib-rituximab (IR) as the standard of care for CLL patients <= 70 years in the frontline setting by improving the progression free (PFS) and overall survival (OS) compared to previous standard chemo-immunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) (Shanafelt et al. NEJM 2019). Quality of life (QOL) was an important secondary endpoint on this trial comparing continuous (IR) vs time-limited (FCR) therapy due to the differing profile of treatment-related toxicities over the short and long-term. E1912 patient-reported outcomes (PROs) results are presented here.